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ABSTRACT
Purpose: Many patients with metastatic bone disease have to use radiopharmaceuticals associated with chemotherapy to relieve bone
pain. The aim of this study was to assess the influence of docetaxel on the biodistribution of samarium-153-EDTMP in bones and other
organs of rats. Methods: Wistar male rats were randomly allocated into 2 groups of 6 rats each. The DS (docetaxel/samarium) group
received docetaxel (15 mg/kg) intraperitoneally  in two cycles 11 days apart. The S (samarium/control) group rats were not treated with
docetaxel. Nine days after chemotherapy, all the rats were injected with 0.1ml of samarium-153-EDTMP via orbital plexus (25µCi).
After 2 hours, the animals were killed and samples of the brain, thyroid, lung, heart, stomach, colon, liver, kidney and both femurs were
removed. The percentage radioactivity of each sample (% ATI/g) was determined in an automatic gamma-counter (Wizard-1470,
Perkin-Elmer, Finland). Results: On the 9th day after the administration of the 2nd chemotherapy cycle, the rats had a significant weight
loss (314.50±22.09g) compared (p<0.5) to pre-treatment weight (353.66± 22.8). The % ATI/g in the samples of rats treated with
samarium-153-EDTMP had a significant reduction in the right femur, left femur, kidney, liver and lungs of animals treated with docetaxel,
compared to the control rats. Conclusion: The combination of docetaxel and samarium-153-EDTMP was associated with a lower
response rate in the biodistribution of the radiopharmaceutical to targeted tissues. Further investigation into the impact of docetaxel on
biodistribution of samarium-153-EDTMP would complement the findings of this study.
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RESUMO
Objetivo: Muitos pacientes com metástases ósseas são tratados com radiofármacos associados com quimioterapia para alívio da dor
óssea. O objetivo do trabalho foi estudar a influência do docetaxel na biodistribuição do EDTMP-153-samário nos ossos e outros órgãos
de ratos. Métodos: Ratos Wistar foram aleatoriamente alocados em 2 grupos de 6 animais cada. O grupo DS (docetaxel/samário)
recebeu docetaxel (15 mg/kg) intraperitoneal em dois ciclos com 11 dias de intervalo. Os ratos do grupo S (samário/controle) não foram
tratados com docetaxel. Nove dias após a quimioterapia, todos os animais receberam 0,1ml de EDTMP-153-samário via plexo orbital
(25µCi). Após 2 horas, os animais foram mortos e feitas biópsias de cérebro, tireóide, pulmão, coração, estômago, cólon, fígado, rim e
fêmures. O percentual de radioatividade por grama (%ATI/g) de tecido de cada biópsia foi determinado em contador gama automático
(Wizard-1470, Perkin-Elmer, Finland). Resultados: No 9º após 2º ciclo de docetaxel os ratos tiveram perda de peso significante,
passando de 353,66± 22,8g (controle/pré-tratamento) para 314,50±22,09g (p<0,5). Os % ATI/g nos órgãos dos ratos tratados com
EDTMP-153–samário e docataxel tiveram redução significante nos fêmures direito e esquerdo, rim, fígado e pulmão, quando comparados
com os não tratados com docetaxel. Conclusão: A combinação de docetaxel com EDTMP-153-samário foi associada com resposta mais
baixa na biodistribuição do radiofármaco em órgãos alvo. Futuras investigações sobre o impacto do docetaxel na biodistribuição do
EDTMP-153-samário poderão complementar os achados teste estudo.
Descritores: Taxóides. Samário. Disponibilidade Biológica. Quimioterapia. Ratos.
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Introduction
Bone metastases are a frequent complication of cancer,
occurring in up 70% of patients suffering from advanced breast or
prostate cancer1. Bone metastases patients often present with
severe bone pain, especially in the advanced stage of disease1,2.
The major pain mechanism of small metastases appears to be the
stimulation of nerve endings in the endosteum by a variety of
chemical mediators. Larger bone metastases produce stretching of
the periosteum, which leads to pain2. The resulting bone pain
interferes with the patient’s quality of life and requires effective
treatment. Unfortunately, various non-radiotherapeutic modalities
such as analgesics, hormone therapy, orchidectomy, cytostatic and
cytotoxic drugs, bisphosphonates, and surgery are not effective in
all cases, especially in the late stage of the disease1,2. Systemic
radionuclide therapy using boneseeking radiopharmaceuticals is
considered a valuable and effective method for treating patients
with widespread skeletal metastases and increased bone turnover,
especially in patients with bone metastases from prostate and breast
cancer3,4,5.
In the 1980s the radiopharmaceutical samarium-153
ethylenediamine tetramethylene phosphonate (Sm-153-EDTMP)
with short physical half-life was developed, and has been considered
effective in the treatment of bone pain4,5. Docetaxel is one of the
taxane class chemotherapies  that is being increasingly used to treat
various solid tumors, including those of prostate and breast cancer.
It acts by Bcl-2 protein inactivation in the metastatic cells, causing
the death of tumor cells by apoptosis6. In patients with prostate
cancer, docetaxel has been suggested in various studies as the
first-line choice for treating metastatic hormone-refractory disease.
This treatment increases survival, compared to previously accepted
chemotherapy schemes6.
A significant number of patients with metastatic bone
disease are often subjected to a series of concomitant treatments,
including the use of radioisotopes to relieve bone pain, associated
with chemotherapy. Accordingly, the aim of this study was to
assess the influence of docetaxel on the biodistribution of
Sm-153-EDTMP, especially in the bones of rats, enabling a more
thorough knowledge of its applicability.
Methods
We used male rats provided by the Health Science Center
vivarium, Federal University of Rio Grande do Norte, Brazil. The
animals were randomly allocated into 2 groups of 6 rats each. They
were weighed and placed in individual cages with water and food
(Labina Purina®) “ad libitum” and acclimatized in the lab for 7
days. The rats were kept under temperature (21ºC), humidity
(60 - 70%) and lighting (12 / 12 hour cycle light / dark) control and
they were handled in accordance with International Standards of
Care and Use of Laboratory Animals, following the guidelines of
the Brazilian College of Animal Experimentation.
The animals of the DS group (docetaxel/samarium) were
administered docetaxel (Trixotene®, Novartis, São Paulo, Brazil),
intraperitoneally, using a 15 mg/kg dose in two  administration
cycles 11 days apart. The S group (samarium/control) rats were not
treated with docetaxel. The animals remained under observation
for 9 days after the 2nd cycle and  were then injected with 0.1
mL of Sm-153-EDTMP via the orbital plexus, corresponding to
radioactivity of 925 Bq (25µCi). Two hours after radiopharmaceutical
administration, the animals were killed with an anesthesia
overdose (thiopental sodium, via the intracardiac  cannula) and
underwent surgery for removal of samples from the brain, thyroid,
lung, heart, stomach, colon, liver, kidney and both femurs. The
tissue samples were washed in 0.9% saline, weighed on a
precision scale (Mark 160®, Bel equipment, Italy) and their
radioactivity was determined in an automatic gamma counter
(Wizard 1470, Perkin-Elmer, Finland). The results are shown in
counts per minute (CPM), corrected by disintegrations per minute
(DPM). The efficiency of the gamma counter was 86%, as specified
by the manufacturer. The specific activity of each sample was
calculated by dividing its absolute count DPM by its weight
(DPM/g). The percentage of radioactivity of each sample
(% ATI/g) was calculated by dividing its specific activity (DPM/g)
by the total radioactivity injected in each animal. The total activity
administered to each animal was calculated from the average of
three patterns with the same volume injected.
The data were expressed as mean ± standard deviation.
Statistical analysis for comparison between groups was performed
by the Student and Tukey tests, using a significance level of 0.05.
Results
No animal died during the experiment. On the eleventh
day after the 1st chemotherapy cycle with docetaxel, the animals
showed weight loss (mean 329.16±29.2 g), but not  significantly
different from pre-treatment weight (mean 353.66± 22.8).
Meanwhile, on the 9th day after administration of the 2nd
chemotherapy cycle, there was significant weight loss
(314.50±22.09g) compared to pre-treatment weight (Figure 1).
We observed no changes in animal behavior or side effects, such as
diarrhea and hair loss. During the laparotomy to remove organ
samples, few peritoneal adhesions were observed in DS group rats.
No macroscopic changes were detected in the abdominal organs.
The analysis of the percentage of total activity of
Sm-153-EDTMP injected per gram of tissue (% ATI/g) in the
samples analyzed showed greater radiopharmaceutical activity in
the liver, kidney, right femur, left femur and thyroid, when
compared to other organs, in both the DS group (treated with
docetaxel) and control group S (Table 1). In the rats treated with
docetaxel, the Sm-153-EDTMP activity was smaller in all the
organs studied, when compared to the control group, except in the
brain. Using the Student t-test, we showed that this reduction was
statistically significant in the right femur, left femur, kidney, liver
and lungs of animals treated with docetaxel, compared to the
control group rats (p<0.05). Consequently, there was no significant
reduction in radioactivity biodistribution in brain, thyroid, heart,
stomach and colon samples (Table 1).
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TABLE 1 - Comparison of percentage of radioactivity/g (% ATI/g) of samples from each organ of rats treated with Sm-
153-EDTMP (group S) and with docetaxel + Sm-153-EDTMP (group DS)
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FIGURE 1 – The evolution of rats weight comparing pretreatment and after the first (1st) and second (2nd)
post-docetaxel treatment
Mean ± SD, Student t test. S, samarium; DS, docetaxel+samarium.
Organs 
% ATI/g 
p 
Group S Group DS  
Brain 0.01 ± 0.002 0.01 ± 0.005 0.753022 
Thyroid 0.40 ± 0.079 0.30 ± 0.066 0.07301 
Lung 0.17 ± 0.033 0.13 ± 0.025 0.043126 
Heart 0.12 ± 0.019 0.11 ± 0.019 0.300239 
Stomach 0.18 ± 0.042 0.14 ± 0.032 0.091458 
Colon 0.13 ± 0.041 0.11 ± 0.038 0.484202 
Liver 1.48 ± 0.187 0.96 ± 0.267 0.007438 
Kidney 1.21 ± 0.160 0.86 ± 0.144 0.007411 
Femur (right) 0.73 ± 0.105 0.46 ± 0.093 0.002484 
Femur (left) 0.72 ± 0.004 0.50 ± 0.086 0.003599 
* Significant difference, p<0.05, Tukey test.
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Discussion
Bone pain is a common symptom of metastatic cancer and
may be difficult to control with analgesic medication alone. Systemic
agents such as chemotherapy, bisphosphonates and hormonal
therapy, as well as external beam radiation in the form of hemibody
or focal bone irradiation are also used as palliative measures to
control metastatic bone pain7. Radiation in the form of
radiopharmaceuticals has been investigated for the relief of bone
metastasis pain and several systemically administered beta-emitters
have been evaluated for the treatment of painful bone metastases,
two of which (32-P and 89-Sr) have been studied extensively7. Both
agents are effective in relieving pain from osteoblastic metastases,
but they have properties that limit their usefulness. The very high
beta energy of 32-P coupled with a low lesion-to-normal bone ratio
has inhibited widespread use of this radiopharmaceutical as a
palliative agent for bone pain7. The long physical half-life of 89-Sr
(50.5 days) results in a slow delivery of the radiation dose.
Consequently, the onset of pain relief may not occur for several
weeks after administration8. The long half-life can also produce a
prolonged and variable suppression of hematopoietic elements8,
limiting the availability or efficacy of concurrent myelosuppressive
therapies (e.g. external radiation, surgery or chemotherapy) that
these patients frequently require. Therefore, we used 153-samarium
in this study because of its physical and biological proprieties, ease
of use in laboratory, as well as its efficacy in treating bone pain5.
The physical half-life of 153-Sm is 46.3 h, and its beta particle has
a maximum range of 1.7 mm in bone and 3.1 mm in soft tissue.
The gamma emission at 103 keV (29% abundance) is suitable
energy for imaging using standard scintigraphic cameras, and
is low enough result in minimal external exposure levels when
administered at therapeutic levels9. Although many
radiopharmaceuticals have been examined for bone pain
palliation, samarium-153 has been the most extensively examined
in clinical trials. The advantages of radiopharmaceutical use
include the ease of administration, the ability to treat multiple
sites of metastatic disease, the improved potential therapeutic
ratio due to bone location and the potential of combining with
chemotherapy agents and external beam radiation for an enhanced
therapeutic effect4,5.  A subset of trials has suggested improved
pain palliation by combining a radiopharmaceutical agent with
chemotherapy4,5,12.
Taxanes (docetaxel and paclitaxel) are currently one of
the most extensively studied new chemotherapeutic agents for
metastatic breast cancer. Single-agent docetaxel has demonstrated
significant survival advantages over other recognized regimens
in two trials involving patients with anthracycline-pretreated
metastatic breast cancer10.  Some data suggest that docetaxel is one
of the most active agents available for treating these patients11.
The primary objective of this study was to evaluate if
combined chemotherapy interferes with the biodistribution of
Sm-153-EDTMP to bone and other organs. It was based on the
possibility of using Sm-153-EDTMP combined with docetaxel
for the treatment of bone metastasis pain in patients with prostate
or breast cancer.  Recently, Ricci et al.12 reported that Sm-153-
EDTMP is effective in bone pain relief, with minimal toxicity.
When administered in combination with chemotherapy
(estramustine phosphate or mitoxantrone plus prednisone), it
prolonged survival.
Many factors, such as drug therapy, radiation therapy,
surgery, in addition to the pathological process, could affect the
biodistribution of different radiopharmaceuticals13-15. In this work,
when Sm-153-EDTMP was administered to rats previously treated
with docetaxel, the biodistribution of the radiopharmaceutical to
bone, kidney, liver and lung was significantly lower than that of
controls. Based on these data, we can infer that an additional
dose of Sm-153-EDTMP may be necessary to get the desired
pain relief effect when docetaxel is used in combination with
this radiopharmaceutical. It was reported that the average duration
of bone pain palliation in patients treated with Sm-153-EDTMP
alone was about 3–4 months, while it was about 9–10 months in
patients who started receiving estramustine phosphate or
mitoxantrone plus prednisone after treatment with the bone-seeking
radionuclide12. However, information about the clinical effect of
docetaxel associated to Sm-153-EDTMP is scarce. The results
obtained in the present work provide a rationale for further studies
aimed at assessing combined chemotherapy and bone-targeted
radiotherapy (docetaxel plus Sm-153-EDTMP) as a therapeutic
strategy in patients with advanced hormone resistant prostate
cancer.
In conclusion, the combination of docetaxel and Sm-153-
EDTMP was associated with a lower response rate in the
biodistribution of the radiopharmaceutical to targeted tissues.
Further investigation into the impact of docetaxel on the
biodistribution of Sm-153-EDTMP would complement the findings
of this study.
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